甲状腺激素减轻饮食诱导的小鼠非酒精性脂肪性肝炎模型的肝脏脂肪变性、炎症和纤维化
该研究在体外用棕榈酸处理HepG2-TRβ细胞模拟脂毒性,并用西方饮食加15%果糖饮水16周建立C57BL/6J小鼠NASH模型,随后8周在饮水中补充T3/T4。结果显示TH增加线粒体呼吸和脂肪酸氧化,降低肝脏甘油三酯和羟脯氨酸,恢复自噬和线粒体生物合成,减轻氧化应激、炎症和纤维化。
要点
- TH处理降低NASH小鼠肝脏甘油三酯(3.19±0.68 vs. 8.04±0.42 mM/g肝脏)和羟脯氨酸(1.44±0.07 vs. 2.58±0.30 mg/g肝脏)。
- TH恢复溶酶体蛋白水平并清除LC3B-II和p62积累,改善自噬降解。
- TH恢复线粒体生物合成,增加脂肪酸β氧化,降低氧化应激和炎症小体活化。
核心结论
- 在小鼠NASH模型中,TH通过恢复自噬和线粒体生物合成增加脂肪酸β氧化,减少脂毒性、氧化应激、肝脏炎症和纤维化。
- 作者认为激活肝脏甲状腺激素受体可能是治疗NASH的有效策略。
研究设计与样本
- 体外研究使用HepG2-TRβ细胞,用牛血清白蛋白偶联的棕榈酸处理模拟脂毒性条件。
- 体内研究用C57BL/6J小鼠喂食西方饮食并在饮水中添加15%果糖16周建立NASH模型,随后8周在饮水中补充T3/T4。
主要发现
- 在HepG2-TRβ细胞中,TH处理在基础条件和PA处理条件下均增加线粒体呼吸和脂肪酸氧化,并降低LPS和PA刺激的炎症及纤维化反应。
- 与未治疗NASH小鼠相比,TH治疗降低肝脏甘油三酯含量(3.19±0.68 vs. 8.04±0.42 mM/g肝脏)和羟脯氨酸(1.44±0.07 vs. 2.58±0.30 mg/g肝脏)。
- 代谢组学显示NASH小鼠肝脏三酰甘油、二酰甘油、单酰甘油和胆固醇酯种类增加,TH治疗降低这些脂质种类。
- NASH小鼠自噬降解减少,表现为转录因子EB和溶酶体蛋白酶表达降低、LC3B-II和p62积累;TH治疗恢复溶酶体蛋白水平并清除LC3B-II和p62积累。
- TH恢复受损的线粒体生物合成,并降低NASH肝脏升高的氧化应激和炎症小体活化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Nonalcoholic steatohepatitis (NASH) is characterized by hepatic steatosis, lobular inflammation, and fibrosis. Thyroid hormone (TH) reduces steatosis; however, the therapeutic effect of TH on NASH-associated inflammation and fibrosis is not known. This study examined the therapeutic effect of TH on hepatic inflammation and fibrosis during NASH and investigated THs molecular actions on autophagy and mitochondrial biogenesis. Methods: HepG2-TRβ cells were treated with bovine serum albumin-conjugated palmitic acid (PA) to mimic lipotoxic conditions in vitro. Mice with NASH were established by feeding C57BL/6J mice Western diet with 15% fructose in drinking water for 16 weeks. These mice were administered triiodothyronine (T3)/thyroxine (T4) supplemented in drinking water for the next eight weeks. Results: In cultured HepG2-TRβ cells, TH treatment increased mitochondrial respiration and fatty acid oxidation under basal and PA-treated conditions, as well as decreased lipopolysaccharides and PA-stimulated inflammatory and fibrotic responses. In a dietary mouse model of NASH, TH administration decreased hepatic triglyceride content (3.19 ± 0.68 vs. 8.04 ± 0.42 mM/g liver) and hydroxyproline (1.44 ± 0.07 vs. 2.58 ± 0.30 mg/g liver) when compared with mice with untreated NASH. Metabolomics profiling of lipid metabolites showed that mice with NASH had increased triacylglycerol, diacylglycerol, monoacylglycerol, and hepatic cholesterol esters species, and these lipid species were decreased by TH treatment. Mice with NASH also showed decreased autophagic degradation as evidenced by decreased transcription Factor EB and lysosomal protease expression, and accumulation of LC3B-II and p62. TH treatment restored the level of lysosomal proteins and resolved the accumulation of LC3B-II and p62. Impaired mitochondrial biogenesis was also restored by TH. The simultaneous restoration of autophagy and mitochondrial biogenesis by TH increased β-oxidation of fatty acids. Additionally, the elevated oxidative stress and inflammasome activation in NASH liver were also decreased by TH. Conclusions: In a mouse model of NASH, TH restored autophagy and mitochondrial biogenesis to increase β-oxidation of fatty acids and to reduce lipotoxicity, oxidative stress, hepatic inflammation, and fibrosis. Activating thyroid hormone receptor in the liver may represent an effective strategy for NASH treatment.
引用
- Zhou J, Tripathi M, Ho JP, et al. Thyroid Hormone Decreases Hepatic Steatosis, Inflammation, and Fibrosis in a Dietary Mouse Model of Nonalcoholic Steatohepatitis. Thyroid. 2022. PMID: 35317606. doi:10.1089/thy.2021.0621
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。